Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Samsung Medical Center
University Hospital, Essen
Guangxi Medical University
Universitair Ziekenhuis Brussel
Zhejiang University
Henan Cancer Hospital
Fujian Cancer Hospital
Kidney Cancer Research Bureau
National Cheng-Kung University Hospital
Icahn School of Medicine at Mount Sinai
Tang-Du Hospital
Hebei Medical University
Zhongnan Hospital
Zhejiang Cancer Hospital
RenJi Hospital
Sun Yat-sen University
Fudan University
Sun Yat-sen University
Sichuan University
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Xiangya Hospital of Central South University
Fujian Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Yixing People's Hospital
The First Affiliated Hospital of Zhengzhou University
Peking University
Xijing Hospital
The First People's Hospital of Changzhou
Instituto do Cancer do Estado de São Paulo
RenJi Hospital
National Cancer Center, Korea
Royal Marsden NHS Foundation Trust
Tianjin Medical University Cancer Institute and Hospital
OncXerna Theraputics, Inc.
Fujian Medical University
National Cancer Center, Korea
Tianjin Medical University Cancer Institute and Hospital
Nanfang Hospital, Southern Medical University
The First Affiliated Hospital with Nanjing Medical University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Central Hospital of Lishui City
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
LianBio LLC
Hebei Medical University
Samsung Medical Center
Maxinovel Pty., Ltd.
Shanghai Zhongshan Hospital